Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-10-21

Clinical Trial Update: MEG Study of Acute STX209 Effects in ASD [EARLY_Phase 1]

View source ↗

Summary

Early phase 1 trial update of MEG study assessing acute effects of STX209 in autism.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • STX209 (arbaclofen)

Snippet

Sponsor: Timothy Roberts | Conditions: Autism Disorder | EARLY_Phase 1 | Status: COMPLETED | Results posted: 2019-10-21